XiaobingYang GuangzhouChina

Wcn26 Post edited Speaker Card

29 March 2026

Time

Session

2:10 p.m.

3:10 p.m.

HIT! High Impact Clinical Trials 3

- In IgA Nephropathy and Others

Sydney Tang Chair scwtang@hku.hkHong Kong, China

Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)

HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial

XiaobingYang Speaker yxb7829@163.comChina
Efficacy and Safety of Iptacopan in Patients With Iga Nephropathy (IgAN): Final 24-month Results From the Phase Iii Applause-IgAN Study

VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia
ASPIRE Trial: Aspirin Use in Dialysis Patients in China

XueqingYu Speaker yuxueqing@gdph.org.cnChina
Q&A

Main Hall